182 related articles for article (PubMed ID: 33191641)
1. Recognition of Rare, Atypical Manifestations Is Important for Diagnosis and Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Comment on the Article by Delaval et al.
Akiyama M
Arthritis Rheumatol; 2021 Apr; 73(4):719. PubMed ID: 33191641
[No Abstract] [Full Text] [Related]
2. Temporal Arteritis Revealing Antineutrophil Cytoplasmic Antibody-Associated Vasculitides: Are the Visual Outcomes Different From Giant Cell Arteritis? Comment on the Article by Delaval et al.
Samanta J; Naidu G; Mittal S; Nada R; Bal A; Singh R; Gupta V; Gupta A; Sharma A; Pinto B
Arthritis Rheumatol; 2021 Jul; 73(7):1345-1346. PubMed ID: 33605063
[No Abstract] [Full Text] [Related]
3. How can we predict the risk of relapse in antineutrophil cytoplasmic antibody-associated vasculitis? Comment on the article by Walsh et al.
Schönermarck U; Rau S; Fischereder M
Arthritis Rheum; 2012 Sep; 64(9):3057-8; author reply 3058. PubMed ID: 22729507
[No Abstract] [Full Text] [Related]
4. Myeloperoxidase-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Preceded by Temporal Arteritis and Sjögren Syndrome.
Karacabeyli D; Seidman M; Murphy D; Dehghan N
J Clin Rheumatol; 2021 Dec; 27(8S):S663-S665. PubMed ID: 33264254
[No Abstract] [Full Text] [Related]
5. Comment on the Review Article: ANCA-Associated Vasculitis in Latin America. A Systematic Literature Review: About Their Epidemiology and Their Clinical Features by Victor R. Pimentel-Quiroz et al. (J Clin Rheumatol 2022;28:44-51).
Hinojosa-Azaola A; Mejía-Vilet JM
J Clin Rheumatol; 2022 Jun; 28(4):e682-e683. PubMed ID: 35471248
[No Abstract] [Full Text] [Related]
6. Systemic vasculitis: an annual critical digest of the most recent literature.
Della Rossa A; Cioffi E; Elefante E; Ferro F; Parma A; Vagelli R; Talarico R
Clin Exp Rheumatol; 2014; 32(3 Suppl 82):S98-105. PubMed ID: 24854379
[TBL] [Abstract][Full Text] [Related]
7. Rituximab versus cyclophosphamide for remission induction in active, severe antineutrophil cytoplasmic antibody-associated vasculitis: comment on the article by Chung et al.
Jain S; Naidu GSRSNK; Sharma A
Arthritis Rheumatol; 2022 Mar; 74(3):544-545. PubMed ID: 34694068
[No Abstract] [Full Text] [Related]
8. Comment on: Challenge of diagnosing ANCA-associated vasculitis during COVID-19 pandemic: a missed 'window of opportunity' by Giollo et al.
Reffat D; Dziedzic M; O' Riordan A; Adeeb F
Clin Exp Rheumatol; 2023 Sep; 41 Suppl 135(9):3. PubMed ID: 34128793
[No Abstract] [Full Text] [Related]
9. An update on the general management approach to common vasculitides.
Hng M; Zhao SS; Moots RJ
Clin Med (Lond); 2020 Nov; 20(6):572-579. PubMed ID: 33199323
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and management of ANCA associated vasculitis.
Berden A; Göçeroglu A; Jayne D; Luqmani R; Rasmussen N; Bruijn JA; Bajema I
BMJ; 2012 Jan; 344():e26. PubMed ID: 22250224
[No Abstract] [Full Text] [Related]
11. KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis.
Kidney Disease: Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group
Kidney Int; 2024 Mar; 105(3S):S71-S116. PubMed ID: 38388102
[No Abstract] [Full Text] [Related]
12. [Pulmonary manifestations of anti-neutrophil cytoplasmic antibody associated vasculitis].
Elgueta F; Wurmann P; Mac-Namara M; Grandjean J; Ardiles L
Rev Med Chil; 2022 Apr; 150(4):505-511. PubMed ID: 36155760
[TBL] [Abstract][Full Text] [Related]
13. L30. Assessment of vasculitis extent and severity.
Pipitone N; Pazzola G; Muratore F; Salvarani C
Presse Med; 2013 Apr; 42(4 Pt 2):588-9. PubMed ID: 23473914
[No Abstract] [Full Text] [Related]
14. Antineutrophil cytoplasmic antibody-associated vasculitis and VEXAS syndrome: comment on the article by Muratore et al.
Koster MJ; Ghaffar U; Kermani TA; Patnaik MM; Go RS; Mangaonkar AA; Reichard KK; Olteanu H; Warrington KJ
Arthritis Rheumatol; 2023 Aug; 75(8):1490-1492. PubMed ID: 36716119
[No Abstract] [Full Text] [Related]
15. Ectopic Relapse of Anti-neutrophil Cytoplasmic Antibody-associated Pituitary Vasculitis with No Elevation of Anti-neutrophil Cytoplasmic Antibodies after Renal Remission.
Muto R; Inagaki K; Sato N; Sameshima T; Nagakura Y; Baba S; Kato N; Maruyama S; Akahori T
Intern Med; 2020 Dec; 59(24):3187-3193. PubMed ID: 32788533
[TBL] [Abstract][Full Text] [Related]
16. Proteinase 3-antineutrophil cytoplasmic antibody-associated cutaneous vasculitis without systemic involvement.
Brown A; Watchorn RE; Cope NJ; Downs AMR
Clin Exp Dermatol; 2017 Jul; 42(5):582-584. PubMed ID: 28512743
[No Abstract] [Full Text] [Related]
17. Intravenous Immunoglobulin in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Comment on the Article by Crickx et al.
Tamaki H; Calabrese LH; Langford CA; Hajj-Ali RA
Arthritis Rheumatol; 2016 Dec; 68(12):3045-3046. PubMed ID: 27588720
[No Abstract] [Full Text] [Related]
18. Co-existing proteinase 3-antineutrophil cytoplasmic antibody-associated vasculitis with immunoglobulin A nephropathy.
Kucuk A; Solak Y; Gaipov A; Bagcaci S; Esen H; Turk S; Tunc R
Korean J Intern Med; 2016 Jan; 31(1):194-6. PubMed ID: 26767877
[No Abstract] [Full Text] [Related]
19. [Primary systemic ANCA-associated vasculitis--recommendations concerning diagnosis and treatment].
Wiatr E; Gawryluk D
Pneumonol Alergol Pol; 2013; 81(5):479-91. PubMed ID: 23996888
[No Abstract] [Full Text] [Related]
20. Power and Confounding in Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Comment on the Article by Cartin-Ceba et al.
Restrepo-Escobar M; Hernández-Zapata J
Arthritis Rheumatol; 2016 Nov; 68(11):2827-2828. PubMed ID: 27483392
[No Abstract] [Full Text] [Related]
[Next] [New Search]
